FLOT Delivers a Survival Edge Over CROSS in Resectable Lower Oesophageal Adenocarcinoma
Perioperative FLOT chemotherapy now has the clearest comparative signal in resectable adenocarcinoma of the lower oesophagus and oesophagogastric junction. In a systematic review and narrative synthesis of the available comparative literature, the regimen outperformed neoadjuvant chemoradiotherapy using the CROSS protocol on the most clinically consequential endpoints, especially overall survival and progression-free survival.
The question has mattered for years because this disease sits at the junction of two treatment philosophies. CROSS relies on local intensification with concurrent radiation, while FLOT aims to control microscopic systemic spread earlier and more completely. In lower oesophageal and Siewert type I-II oesophagogastric junction adenocarcinoma, where distant relapse often dictates outcome, the systemic component may be the more decisive lever.
The ESOPEC Trial Anchors the Comparative Evidence
The review included 13 reports drawn from nine underlying studies, but one trial dominates the evidence base: ESOPEC, the only direct phase III randomized comparison of FLOT and CROSS. ESOPEC enrolled 438 patients and reported a median follow-up of 55 months, giving the comparison enough time to capture the survival divergence that short follow-up can obscure.
Perioperative FLOT produced a median overall survival of 66 months versus 37 months with CROSS. The hazard ratio for death was 0.70, with a 95% confidence interval of 0.53 to 0.92 and a p value of 0.012. Progression-free survival also favored FLOT, with a hazard ratio of 0.66, a 95% confidence interval of 0.51 to 0.85, and a p value of 0.001.
Those are not subtle differences. They point to a regimen that is doing more than shrinking the primary tumor; it appears to be altering the downstream course of a disease that frequently fails outside the radiation field.
Distant Recurrence Favors Systemic Therapy
The clearest biologic explanation for the survival gap lies in recurrence pattern. Distant recurrence was significantly lower with FLOT, with a 3-year cumulative incidence of 31.5% versus 47.2% for CROSS. The hazard ratio for distant recurrence was 0.59, reinforcing the idea that early systemic chemotherapy is better aligned with the failure mode of this cancer.
Lower oesophageal and gastroesophageal junction adenocarcinomas often spread hematogenously or through occult peritoneal and nodal micrometastatic disease before resection is even considered. Radiation can improve local control, but it cannot sterilize disease already beyond the treatment volume. A taxane- and platinum-based perioperative program, by contrast, can expose micrometastases to treatment before surgery and again after recovery, when residual disease may still be vulnerable.
pCR and Local Control Do Not Tell the Whole Story
Pathologic complete response has long been used as a shorthand for neoadjuvant efficacy, yet this review shows why pCR alone can mislead. CROSS remains strong for local tumor regression, and chemoradiotherapy often produces impressive pathologic downstaging. But in adenocarcinoma of the lower oesophagus and oesophagogastric junction, local response does not necessarily translate into longer life if distant relapse remains common.
The review’s comparative synthesis therefore shifts attention away from an isolated surrogate and back to endpoints that matter at the bedside: survival, progression-free survival, and metastatic failure. A regimen that improves pCR but leaves a large reservoir of later recurrence may look attractive in the pathology suite and disappointing in long-term follow-up.
Evidence Quality Was Formalized, but the Dataset Remains Small
Methodologically, the review followed PRISMA 2020 and used a structured search across PubMed/MEDLINE, Embase, CENTRAL, and ClinicalTrials.gov, with the last search run on 30 June 2026. Risk of bias assessment used RoB 2 for randomized trials and ROBINS-I for observational studies, while certainty of evidence was graded with GRADE. Synthesis followed the SWiM framework, which is appropriate when the included studies are too heterogeneous for a statistically pooled meta-analysis.
The design choices are sensible, but the evidence base is still narrow. Only one randomized phase III study directly compares the two approaches, so the current comparative conclusion is heavily dependent on ESOPEC. Observational and real-world reports can broaden the clinical context, yet they cannot fully resolve confounding from selection, staging differences, surgical quality, or treatment completion.
Why the Result Matters for Treatment Planning
For surgeons, oncologists, and multidisciplinary teams, the practical issue is whether radiation should remain the default comparator when resectable lower oesophageal adenocarcinoma is being discussed. This synthesis suggests the answer is increasingly no, at least when the goal is maximizing survival in fit patients who can tolerate perioperative chemotherapy.
The result also fits the biology of the disease. A tumor at the lower oesophagus and oesophagogastric junction often behaves more like a systemic adenocarcinoma than a purely locoregional neoplasm. If occult metastases are already present early, then a strategy built around chemotherapy has a conceptual advantage over one centered on local radiosensitization.
Short and direct conclusion: the survival signal tracks with the metastatic pattern.
What Still Needs Clarification
Even with a strong randomized signal, several questions remain unresolved in routine practice. The review does not establish whether all Siewert I-II tumors derive the same magnitude of benefit, nor does it settle how comorbidity, frailty, surgical technique, or treatment adherence should influence regimen choice. The comparative balance of toxicity, postoperative recovery, and treatment completion also remains important, because a superior regimen on paper can lose its edge if it is not deliverable in real patients.
The current evidence base also leaves room for better biomarker-driven selection. Tumor biology, nodal burden, and response predictors may eventually separate patients who need intensified systemic therapy from those who still benefit from local chemoradiation. For now, however, the available randomized evidence points in one direction: in resectable lower oesophageal and oesophagogastric junction adenocarcinoma, FLOT has the stronger survival profile and the more favorable distant-control signal than the CROSS protocol.
The unanswered clinical task is not whether one regimen can outperform the other in aggregate. It is which patient subsets, if any, still justify choosing radiation-first treatment when a systemic strategy has already shown a longer median survival and fewer distant relapses.